News Center

HSBC to lose Asia expert as Chairman Mark Tucker announces retirement

HSBC to lose Asia expert as Chairman Mark Tucker announces retirement

By Lawrence White LONDON (Reuters) -HSBC said on Thursday that Chairman Mark Tucker will retire by the end of this year, after nearly eight years in the role at Europe’s biggest bank presiding over its dramatic shrinking and navigating of Sino-U.S. tensions. Tucker, the bank’s first ever externally-recruited Chairman, will remain as a strategic adviser to CEO Georges Elhedery, the bank said, a ...

2025-05-01 22:26:40
Mastercard off to a strong start in 2025 as consumer spending holds up

Mastercard off to a strong start in 2025 as consumer spending holds up

(Reuters) -Mastercard beat Wall Street estimates for first-quarter profit on Thursday as customers kept up spending on its card network despite the economic uncertainty sparked by a global trade war, sending its shares up 1.7% in premarket trading. U.S. consumer spending held up in the reported quarter thanks to wage growth and a resilient labor market, even as tariff-driven turmoil casts a shadow ...

2025-05-01 22:25:27
Hershey posts robust quarterly results on North America snacks demand

Hershey posts robust quarterly results on North America snacks demand

(Reuters) -Hershey posted a smaller-than-expected drop in sales for the first quarter and beat profit estimates on Thursday, helped by steady demand for its salty snacks business in North America. Sales in Hershey’s North America snack business, home to Dot’s pretzels and SkinnyPop popcorn, got a boost as the company reduced prices after several quarters of hikes. Its quarterly organic volume ...

2025-05-01 22:24:18
Arvinas stock tumbles following workforce reduction and trial removals

Arvinas stock tumbles following workforce reduction and trial removals

Investing.com -- Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its development plan. Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology fir ...

2025-05-01 22:23:20